← Back to all trials
Not Yet Recruiting
NCT05661916
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Conditions: Transthyretin-Mediated Amyloidosis
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 132
Sponsor: Alnylam Pharmaceuticals
Location: United Kingdom
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.
Eligibility Criteria
Inclusion Criteria:Body mass index (BMI) ≥18.0 kg/m^2 and ≤30 kg/m^2 assessed at Screening.Exclusion Criteria:Has an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73m^2
at screening.Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin above the upper limit of normal (ULN).
Source: ClinicalTrials.gov (NCT05661916). StuddyBuddy aggregates publicly available trial information.
